News

There are hundreds of conditions that have itch as an underlying symptom, according to Brian S. Kim, MD, MTR, the Sol and Clara Kest professor of dermatology and vice chair of research at Icahn School ...
Advancements in itch therapeutics have evolved rapidly, offering patients with various itch-driven diseases multiple options that target the source of their itch. Itch exists on a spectrum, according ...
About Septerna Inc. Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discover ...
Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...
Septerna (NASDAQ:SEPN – Get Free Report) is projected to announce its Q1 2025 earnings results on Thursday, June 26th. Analysts expect the company to announce earnings of ($0.38) per share for ...
Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to read my most recent analysis.
Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform.
Septerna anticipates initiating a Phase 1 clinical trial to assess safety, tolerability, PK, and pharmacodynamics (through an icatibant skin challenge) of SEP-631 in healthy volunteers in the third ...
Septerna continues to advance multiple lead compounds with distinct chemical structures unrelated to its first-generation oral small molecule, SEP-786, each with favorable pharmacokinetics (PK ...
--Septerna, Inc., a biotechnology company pioneering a new era of G protein-coupled receptor drug discovery, today highlighted key business updates and upcoming milestones and reported financial ...